Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Daniel C. Maneval"'
Autor:
Tiantian Cui, Sergio Corrales-Guerrero, Veronica Castro-Aceituno, Sindhu Nair, Daniel C. Maneval, Curtis Monnig, Patrick Kearney, Sam Ellis, Nicholas Raheja, Neil Raheja, Terence M. Williams
Publikováno v:
Molecular Therapy: Oncolytics, Vol 30, Iss , Pp 181-192 (2023)
Albumin is an attractive candidate carrier for the development of novel therapeutic drugs. Gemcitabine has been FDA approved for the treatment of solid tumors; however, new drugs that optimize gemcitabine delivery are not available for clinical use.
Externí odkaz:
https://doaj.org/article/082c3e3a95e54afc8d405e1d14c0a9ab
Autor:
Thomas Heineman, Megan Baumgart, Charvi Nanavati, Nash Gabrail, Scott A. Van Wart, Donald E. Mager, Daniel C. Maneval, Anas M. Fathallah, Rose E. Sekulovich
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1875-1885 (2021)
Abstract This open‐label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB/IV non‐small cell lung cancer (NSCL
Externí odkaz:
https://doaj.org/article/761157f9b06d471aacfa5fededd00753
Publikováno v:
Drug Delivery, Vol 26, Iss 1, Pp 98-106 (2019)
ENHANZE® drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degr
Externí odkaz:
https://doaj.org/article/db94eb4355944ba4a608ab317f5696f8
Autor:
Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD
Publikováno v:
Current Therapeutic Research, Vol 93, Iss , Pp 100604- (2020)
ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/
Externí odkaz:
https://doaj.org/article/9727f714ed4549758640d27883f0f639
Autor:
Curtis B. Thompson, Daniel C. Maneval, Michael J. LaBarre, Darin M. Taverna, Daniel D. Von Hoff, Haiyong Han, Clifford J. Whatcott, Mark D. Pagel, Sheryl A. Garrovillo, Barbara Blouw, Sanna Rosengren, Ryan J. Osgood, Chunmei Zhao, Jessica A. Cowell, H. Michael Shepard, Xiaoming Li
AsPC-1 parental cells (AsPC-1-P) engineered to overexpress HAS3 (AsPC-1/HAS3, see Materials and Methods) produced more HA in the peritumoral matrix and the stroma.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8848a82ee33c79fb2dbd4b4d9bfa5878
https://doi.org/10.1158/1078-0432.22470269.v1
https://doi.org/10.1158/1078-0432.22470269.v1
Autor:
Curtis B. Thompson, Daniel C. Maneval, Michael J. LaBarre, Darin M. Taverna, Daniel D. Von Hoff, Haiyong Han, Clifford J. Whatcott, Mark D. Pagel, Sheryl A. Garrovillo, Barbara Blouw, Sanna Rosengren, Ryan J. Osgood, Chunmei Zhao, Jessica A. Cowell, H. Michael Shepard, Xiaoming Li
Purpose: The tumor microenvironment (TME) evolves to support tumor progression. One marker of more aggressive malignancy is hyaluronan (HA) accumulation. Here, we characterize biological and physical changes associated with HA-accumulating (HA-high)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c31d164a97d3bdde1c5c4fecf6f5286
https://doi.org/10.1158/1078-0432.c.6527495
https://doi.org/10.1158/1078-0432.c.6527495
Autor:
Marie A, Printz, Barry J, Sugarman, Rudolph D, Paladini, Michael C, Jorge, Yan, Wang, David W, Kang, Daniel C, Maneval, Michael J, LaBarre
Publikováno v:
The AAPS Journal. 24
Multiple FDA-approved and clinical-development stage therapeutics include recombinant human hyaluronidase PH20 (rHuPH20) to facilitate subcutaneous administration. As rHuPH20-reactive antibodies potentially interact with endogenous PH20, we investiga
Autor:
Aleksandra Drelich, Miriam A. Giardini, Pavla Fajtová, Drake M. Mellott, Vivian Hook, Thomas D. Meek, Jason C. Hsu, Demetrios H. Kostomiris, Aaron F. Carlin, Frank M. Raushel, Klaudia I. Kocurek, Jair L. Siqueira-Neto, Zane W. Taylor, Anthony J. O’Donoghue, Felix W Frueh, Jiyun Zhu, Ardala Katzfuss, Chien Te K. Tseng, Sungjun Beck, Hong Wang, Brett L. Hurst, Laura Beretta, Ken Hirata, James H. McKerrow, Alex E. Clark, Linfeng Li, Daniel C Maneval, Danielle E. Skinner, Balachandra Chenna, Vivian Tat, Michael C Yoon
Publikováno v:
ACS Chemical Biology. 16:642-650
Host-cell cysteine proteases play an essential role in the processing of the viral spike protein of SARS coronaviruses. K777, an irreversible, covalent inactivator of cysteine proteases that has recently completed phase 1 clinical trials, reduced SAR
Autor:
Alex B. Blair, Jianxin Wang, John Davelaar, Andrew Baker, Keyu Li, Nan Niu, Junke Wang, Yingkuan Shao, Vanessa Funes, Pan Li, Jonathan A. Pachter, Daniel C. Maneval, Felipe Dezem, Jasmine Plummer, Keith Syson Chan, Jun Gong, Andrew E. Hendifar, Stephen J. Pandol, Richard Burkhart, Yuqing Zhang, Lei Zheng, Arsen Osipov
Publikováno v:
Gastroenterology. 163:1267-1280.e7
The stroma in pancreatic ductal adenocarcinoma (PDAC) contributes to its immunosuppressive nature and therapeutic resistance. Herein we sought to modify signaling and enhance immunotherapy efficacy by targeting multiple stromal components through bot
Autor:
Nadia A. Golden, Kasi E. Russell-Lodrigue, Rudolph Bohm, Daniel C Maneval, Kenneth S. Plante, James H. McKerrow, Sierra Simpson, Jessica A. Plante, Jay Rappaport, Felix W Frueh, Jason Dufour, Chad J. Roy, Sky Spencer, Pyone P. Aye, Robert V Blair, Kathy Powell
The COVID-19 pandemic resulted from global infection by the SARS-CoV-2 coronavirus and rapidly emerged as an urgent health issue requiring effective treatments. To initiate infection, the Spike protein of SARS-CoV-2 requires proteolytic processing me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa7c47f94e6e5a0afb0cb789486fccd1
https://doi.org/10.1101/2021.07.20.453127
https://doi.org/10.1101/2021.07.20.453127